BPTH · Bio-Path Holdings Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $38.0K | $275.0K | $4.05M | $1.98M | - | $1.32M | $1.87M | $2.29M | - | $2.29M |
| SG&A | $259.0K | $213.0K | $514.0K | $1.26M | - | $1.32M | $1.17M | $1.41M | - | $984.0K |
| Total Operating Expenses | $297.0K | $488.0K | $4.56M | $3.24M | - | $2.63M | $3.04M | $3.69M | - | $3.28M |
| D&A | - | - | - | $2.0K | - | - | $28.0K | $22.0K | - | - |
| Operating Income | ($297.0K) | ($488.0K) | ($4.56M) | ($3.24M) | - | ($2.63M) | ($3.04M) | ($3.69M) | - | ($3.28M) |
| Interest Expense | - | - | $35.0K | $5.0K | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($270.0K) | ($976.0K) | ($4.60M) | ($2.85M) | - | ($2.12M) | ($1.87M) | ($3.16M) | - | ($3.20M) |
| EPS - Basic | - | - | ($0.55) | ($0.40) | - | ($0.70) | ($1.16) | ($4.88) | - | ($0.32) |
| EPS - Diluted | ($0.03) | ($0.11) | ($0.55) | ($0.40) | - | ($0.70) | ($1.16) | ($4.88) | - | ($0.32) |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.0K | $0 | $0 | $122.0K | $1.17M | $562.0K | $4.01M | $188.0K | $1.05M | $2.35M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.16M | $4.90M | $3.48M | $2.44M | $1.27M | $1.04M | $766.0K | $1.75M | $457.0K | $277.0K |
| Current Assets | $667.0K | $663.0K | $680.0K | $2.12M | $3.78M | $2.90M | $5.02M | $1.64M | $3.04M | $4.80M |
| Total Assets | $677.0K | $690.0K | $746.0K | $2.19M | $3.88M | $2.96M | $5.12M | $1.77M | $3.22M | $5.02M |
| Current Liabilities | $8.88M | $8.68M | $7.86M | $4.74M | $3.29M | $3.38M | $3.01M | $3.81M | $1.91M | $1.36M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.90M | $8.69M | $7.90M | $4.78M | $3.73M | $3.68M | $3.83M | $4.39M | $2.78M | $2.50M |
| Stockholders' Equity | ($8.49M) | ($8.00M) | ($7.16M) | ($2.59M) | $154.0K | ($712.0K) | $1.29M | ($2.63M) | $441.0K | $2.52M |
| Retained Earnings | ($126.17M) | ($125.93M) | ($124.95M) | ($120.35M) | ($117.50M) | ($114.75M) | ($112.63M) | ($110.76M) | ($107.61M) | ($104.23M) |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($38.0K) | - | - | ($1.31M) | - | - | ($4.27M) | ($1.04M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $50.0K | - | - | $262.0K | - | - | $7.22M | $174.0K | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -39.9% | -141.4% | -616.2% | -129.9% | - | -71.3% | -36.5% | -178.6% | - | -63.7% |
| Return on equity | 3.2% | 12.2% | 64.2% | 110.2% | - | 297.1% | -144.8% | 120.3% | - | -126.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.08 | 0.08 | 0.09 | 0.45 | 1.15 | 0.86 | 1.67 | 0.43 | 1.60 | 3.54 |
| Quick ratio | 0.08 | 0.08 | 0.09 | 0.45 | 1.15 | 0.86 | 1.67 | 0.43 | 1.60 | 3.54 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.03 | 0.36 | 0.17 | 1.33 | 0.05 | 0.55 | 1.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -130.3x | -648.2x | - | - | - | - | - | - |
| Equity multiplier | -0.08 | -0.09 | -0.10 | -0.85 | 25.21 | -4.16 | 3.96 | -0.67 | 7.30 | 1.99 |
| Liabilities / Assets | 13.14 | 12.60 | 10.60 | 2.18 | 0.96 | 1.24 | 0.75 | 2.48 | 0.86 | 0.50 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 90.8% | 81.5% | -50.2% | 12.3% | - | 19.6% | 28.4% | 30.2% | - | 7.6% |
| Net income growth (YoY) | 90.5% | 53.9% | -146.0% | 9.7% | - | 33.9% | 55.9% | 40.1% | - | 9.5% |
| EPS growth (YoY) | 92.5% | 84.3% | 52.6% | 91.8% | - | -118.7% | -118.9% | -639.4% | - | 34.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -227.8% | -1024.2% | - | 1.4% | -65.1% | - | -74.4% | - | -96.9% | -84.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIO-PATH HOLDINGS INC against the 5 most active filers in the same SIC group.